Erasca releases early-stage RAS drug data amid legal dispute with Revolution Medicines
read at Endpoints ↗Neutral
Erasca has released early-stage data on its RAS-targeting compound, doing so after receiving a legal threat from rival Revolution Medicines.
Revolution recently announced a new drug that revived hopes for treating pancreatic cancer, intensifying competition in the RAS space.
The data release raises the prospect of a courtroom battle as both companies vie for market leadership, and investors are closely monitoring the developments.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Erasca reports RAS cancer drug data after legal threat from Revolution”
read at Endpoints ↗93 words · retrieved Apr 27
comments(0)
5-min edit window · permanent after that